Chrysoeriol-Mediated Neuroprotection in Parkinson’s Disease in Mice: Targeting Apoptosis, α-Synuclein Accumulation, and Functional Recovery

Read full text Summarise with VIRAT
Authors: Mehak Ali, Mehwish Mehreen, Saima Batool, Shahrukh Khan, Aneeqa Noor, Sara Mumtaz, Saima Zafar
Cited by: 0
References: 49

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

, remains largely unexplored. This study fills a critical gap by being the first to systematically assess chrysoeriol's neuroprotective effects in a PD mouse model. We evaluated the effects of 5 mg/kg chrysoeriol administered intraperitoneally (IP) for 14 days in an acute 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD model. Behavioral tests showed notable recovery, as chrysoeriol eliminated deficits in motor function, coordination, and balance, as assessed by the pole test, forced swim test, and tail suspension test. It also mitigated exploratory and locomotor deficits in the open field test, and the Y-maze test revealed improved spatial and learning memory. Hematoxylin and eosin staining indicated a significant reduction in neuronal damage across key brain regions. qPCR analysis showed reduced 1-methyl-4-phenylpyridinium (MPP+)-induced toxicity, downregulation of α-synuclein, and an improved Bcl-2/Bax ratio. These findings suggest chrysoeriol may protect against MPP+-induced apoptosis in mice, potentially via the PI3K/Akt signaling pathway, and reduces mitochondrial damage by downregulating α-synuclein.

Fields of Study & Subjects

Parkinson's Disease Mechanisms and Treatments Nuclear Receptors and Signaling Neuroprotection in Cerebral Ischemia

Publication details

Journal / source
The Yale Journal of Biology and Medicine
Volume
99
Issue
1
Pages
111–126
Publication date
31 March 2026
Language
EN